Cardiff Oncology, Inc. (FRA:XE7C)
Germany
· Delayed Price · Currency is EUR 1.750
+0.076 (4.54%)
At close: Dec 4, 2025
Cardiff Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.5 | 0.68 | 0.49 | 0.39 | 0.36 | 0.37 | Upgrade
|
| Revenue Growth (YoY) | -27.18% | 39.96% | 26.42% | 7.52% | -1.91% | 49.61% | Upgrade
|
| Cost of Revenue | 39.97 | 36.85 | 32.86 | 27.11 | 17.38 | 11.24 | Upgrade
|
| Gross Profit | -39.47 | -36.17 | -32.37 | -26.72 | -17.02 | -10.87 | Upgrade
|
| Selling, General & Admin | 14.24 | 12.48 | 13.04 | 13.18 | 11.84 | 8.22 | Upgrade
|
| Operating Expenses | 14.24 | 12.48 | 13.04 | 13.18 | 11.84 | 8.22 | Upgrade
|
| Operating Income | -53.71 | -48.65 | -45.41 | -39.9 | -28.86 | -19.09 | Upgrade
|
| Interest Expense | - | - | - | - | - | -0 | Upgrade
|
| Interest & Investment Income | 3.28 | 3.26 | 4.07 | 1.58 | 0.26 | 0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | -0.04 | -0.1 | -0.38 | 0.3 | -0.31 | Upgrade
|
| EBT Excluding Unusual Items | -50.42 | -45.43 | -41.44 | -38.7 | -28.29 | -19.31 | Upgrade
|
| Pretax Income | -50.42 | -45.43 | -41.44 | -38.7 | -28.29 | -19.31 | Upgrade
|
| Net Income | -50.42 | -45.43 | -41.44 | -38.7 | -28.29 | -19.31 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 3.29 | Upgrade
|
| Net Income to Common | -50.45 | -45.46 | -41.47 | -38.73 | -28.32 | -22.6 | Upgrade
|
| Shares Outstanding (Basic) | 64 | 48 | 45 | 44 | 39 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 64 | 48 | 45 | 44 | 39 | 21 | Upgrade
|
| Shares Change (YoY) | 40.37% | 6.65% | 2.47% | 11.71% | 86.97% | 249.44% | Upgrade
|
| EPS (Basic) | -0.79 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | Upgrade
|
| EPS (Diluted) | -0.79 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | Upgrade
|
| Free Cash Flow | -42.27 | -37.77 | -31.47 | -34.83 | -23.25 | -16.53 | Upgrade
|
| Free Cash Flow Per Share | -0.67 | -0.79 | -0.70 | -0.80 | -0.60 | -0.79 | Upgrade
|
| Operating Margin | -10719.56% | -7123.13% | -9305.74% | -10337.31% | -8037.60% | -5214.75% | Upgrade
|
| Profit Margin | -10069.06% | -6655.20% | -8496.93% | -10033.16% | -7887.19% | -6174.32% | Upgrade
|
| Free Cash Flow Margin | -8436.53% | -5530.45% | -6448.57% | -9022.28% | -6474.93% | -4515.30% | Upgrade
|
| EBITDA | -53.33 | -48.25 | -45.01 | -39.67 | -28.4 | -18.62 | Upgrade
|
| D&A For EBITDA | 0.37 | 0.4 | 0.4 | 0.24 | 0.45 | 0.47 | Upgrade
|
| EBIT | -53.71 | -48.65 | -45.41 | -39.9 | -28.86 | -19.09 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.